These are exceptionally strong results, and could put GSK in pole position in COPD – a welcome reversal of fortune after a string of underwhelming results from Breo (fluticasone furoate/vilanterol).

The precise mechanism through which fluticasone furoate affects COPD and asthma symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (eg ...